title: Correlation between clinical course and quantitative analysis of the ischemia related artery in patients with unstable angina pectoris, refractory to medical treatment. Results of two randomized trials. The European Cooperative Study Group.
abstract: Patients with unstable angina, refractory to intensive medical therapy, are at high risk for developing thrombotic complications, such as recurrent ischemia, myocardial infarction and coronary occlusion during coronary angioplasty. As both platelet aggregation and/or thrombus formation play an important role in this ongoing ischemic process, a monoclonal platelet GPIIb/IIIa receptor antibody (c7E3) or thrombolytic therapy (alteplase) might be able to modify the clinical course and underlying coronary lesion morphology. To evaluate whether alteplase or c7E3 could influence the incidence of complications, we randomized 36 and 60 patients, respectively to alteplase or placebo, or c7E3 or placebo. All patients exhibited dynamic ECG changes and recurrent pain attacks, despite maximal tolerated medical therapy. Patients were randomized in both studies after initial angiography had demonstrated a culprit lesion amenable for angioplasty. After study drug infusion quantitative angiography was repeated and angioplasty performed. Recurrent ischemia during study drug infusion occurred in 5, 6, 9 and 16 patients from the alteplase, placebo, c7E3 and placebo group, respectively. Major events defined as death, myocardial infarction or urgent intervention occurred in 7, 3, 1 and 7 patients, respectively. Two patients died: one in the alteplase group and one in the placebo group from the c7E3 study. The first patient due to retroperitoneal hemorrhage, the second as a result of recurrent infarction. Qualitative angiography showed resolution of clots in the c7E3 group only, while the same group of patients showed in 20% an improvement in TIMI flow grade, without deterioration in any patient from this group.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Thoraxcenter, Erasmus University, Rotterdam, The Netherlands.
authors.forename: M J
authors.initials: MJ
authors.lastname: van den Brand
authors.forename: A
authors.initials: A
authors.lastname: van Miltenburg
authors.forename: M J
authors.initials: MJ
authors.lastname: de Boer
authors.forename: L R
authors.initials: LR
authors.lastname: van der Wieken
authors.forename: P J
authors.initials: PJ
authors.lastname: de Feyter
authors.forename: M L
authors.initials: ML
authors.lastname: Simoons
mesh_terms: D000077284:Abciximab; D000328:Adult; D000368:Aged; D000789:Angina, Unstable / Q000150:complications* / Q000000981:diagnostic imaging / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017023:Coronary Angiography; D003327:Coronary Disease / Q000150:complications*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors*; D012008:Recurrence; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010980:Platelet Membrane Glycoproteins; D010959:Tissue Plasminogen Activator; D000077284:Abciximab